Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.
Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.
How do comorbidities like metabolic syndrome impact the risk of MS? For instance, what do we know about why metabolic syndrome results in longer diagnostic delays?
So, it's an important question and because obesity is so common in the general population, so we recognize now from a number of studies In the United States and Europe, for example, that obesity does increase your risk of multiple sclerosis. And we think that's in part related to the fact that our fat tissues or adipose tissue is metabolically active, it secretes pro-inflammatory cytokines and free fatty acids. And so, it confers an increased risk of MS. And as you mentioned, it is one of the factors that can increase diagnostic delays.
It has also been demonstrated to affect some of the parameters that clinicians seem to follow when we're following people with multiple sclerosis. So, brain atrophy seems to be greater, and individuals with multi Multiple Sclerosis who are obese than nonobese. If we're looking at the thickness of the retinal layer in the eye that also seems to thin more quickly in individuals who are obese so suggesting some important impacts on outcomes and in children with multiple sclerosis. A less common group but nonetheless an important one. There's at least one study that suggests that the response to disease-modifying therapies may not be as good in children who are obese, which may suggest we need to think differently about their treatment.
So, it's very important, both in terms of you know, confers risks. So what can we do to reduce the risk of MS, we could work on obesity, but once somebody is diagnosed with MS, it will be important to try and help individuals achieve, you know, healthier weight through physical activity, healthy eating and working with them around the strategies to sustain those behaviors and trying to prevent it and people who are not obese at the time of diagnosis trying to head that off from the beginning.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More